Wang Yaoyao, Yang Xiancong, Liu Yalin, Li Youjie
Department of Pediatrics of Yantai Affiliated Hospital, The Second Clinical Medical College of Binzhou Medical University, Yantai, Shandong, China.
Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, Shandong, China.
Front Immunol. 2025 Mar 10;16:1505247. doi: 10.3389/fimmu.2025.1505247. eCollection 2025.
Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy. Traditional chemotherapy methods not only bring serious side effects, but also lead to high recurrence rate and drug resistance in some patients. However, as an emerging therapeutic strategy, immunotherapy has shown great potential in the field of AML treatment in recent years. At present, common immunotherapy methods for AML include monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors. With the deepening of research and technological progress, especially the application of nanotechnology in medicine, new immunotherapy is expected to become one of the important means for the treatment of acute myeloid leukemia in the future.
急性髓系白血病（AML）是一种高度侵袭性的血液系统恶性肿瘤。传统化疗方法不仅会带来严重的副作用，还会导致一些患者的复发率高和耐药性。然而，作为一种新兴的治疗策略，免疫疗法近年来在AML治疗领域显示出巨大潜力。目前，AML常见的免疫疗法包括单克隆抗体、嵌合抗原受体T细胞（CAR-T）疗法和免疫检查点抑制剂。随着研究的深入和技术的进步，特别是纳米技术在医学中的应用，新型免疫疗法有望成为未来治疗急性髓系白血病的重要手段之一。
